GlassScriptPhysician profile
Eleazar E Calero
NPI 1336280122
$10,363.74
in general payments reported to CMS, 2019-2025
40 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,194 · 2020: $1,409 · 2021: $1,380 · 2022: $1,585 · 2023: $1,192 · 2024: $1,204 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,795.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,749.04 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,748.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $841.21 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $675.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.80 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $531.19 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $486.26 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.81 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $357.86 | 2021-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $315.09 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $260.08 | 2020-2025 | Verquvo |
| Sunovion Pharmaceuticals INC. | $255.27 | 2021-2022 | |
| Abbvie INC. | $236.26 | 2021-2025 | Creon, Linzess |
| Abbott Laboratories | $220.13 | 2022-2023 | Freestyle Libre 3 |
| Pfizer INC. | $200.35 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleazar Calero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.